ARMP

Armata Pharmctcl

• TipRanks·08/13 10:15

  Armata: Buy Rating Reiterated as AP-SA02 Advances Toward 2H26 Phase 3 Start; $15 Price Target Maintained

• Benzinga·08/12 20:29

  Armata Pharmaceuticals Q2 EPS $(0.27) Beats $(0.45) Estimate, Sales $2.510M Beat $420.000K Estimate

• Seeking Alpha·08/12 20:18

  Armata Pharmaceuticals GAAP EPS of -$0.27 beats by $0.18, revenue of $2.51M

• Dow Jones·08/12 20:05

  Press Release: Armata Pharmaceuticals Announces -3-

• Dow Jones·08/12 20:05

  *Armata Pharmaceuticals 2Q Loss/Shr 27c >ARMP

• Seeking Alpha·08/06 11:31

  Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

• NASDAQ·07/21 11:05

  Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?

• NASDAQ·07/21 03:01

  Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch

• Benzinga·07/20 16:45

  Why Is Armata Pharma Stock Gaining Monday?

• TipRanks·07/20 12:50

  Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Armata Pharmaceuticals (ARMP)

• TipRanks·07/20 11:28

  Armata Advances AP-SA02 Toward Phase 3 Trial Launch

• Benzinga·07/20 11:13

  Armata Pharma Promotes David House To CFO

• Benzinga·07/20 11:12

  Armata Announces Significant Clinical, Regulatory, Manufacturing And Operational Progress Supporting Advancement Of AP-SA02 Toward Planned Phase 3 Superiority Study For Adjunct Treatment Of Complicated Bacteremia

• TipRanks·07/20 11:11

  Armata provides update on AP-SA02 studies

• TipRanks·07/20 11:11

  Armata promotes David House to CFO